87th European Atherosclerosis Society Congress

  • Date:
  • Location: Maastricht, Netherlands

During the 87th European Atherosclerosis Society Congress in Maastricht, Netherlands, the company will present a combined analysis of data in renal-impaired patients from ORION-1 and ORION-7 during an oral abstract session on May 27, 2019. Data in homozygous familial hypercholesterolemia patients from ORION-2 will be presented during a late-breaking abstract session on the same day.

  • ORION-1 is a Phase 2, placebo-controlled, double-blind, randomized trial to evaluate the efficacy, safety, and tolerability of inclisiran in participants with ASCVD or ASCVD-risk equivalents and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies.
  • ORION-7 is a Phase 1, single-dose, open-label trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of inclisiran in participants with mild, moderate, and severe renal impairment compared to participants with normal renal function.
  • ORION-2 is a Phase 2 pilot study to assess the safety, tolerability, and efficacy of inclisiran in participants with homozygous familial hypercholesterolemia.

Contact Us

The Medicines Company
8 Sylvan Way
Parsippany, NJ 07054 USA
Tel 973 290 6000
Toll-free 800 388 1183
Global Medical Information

Human Resources
Verification of employment
Tel 973 290 6361
Fax 862 207 6361

Investors Relations

Krishna Gorti, MD
Tel 973 290 6122

Media Inquiries

Michael Blash
Tel 973 290 6100